Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Divan A Burger

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The AAPS Journal|May 6, 2024
Correction: Group-by-Treatment Interaction Effects in Comparative Bioavailability StudiesHelmut Schütz, Divan A Burger, Erik Cobo, et al.
The AAPS Journal|April 17, 2024
Group-by-Treatment Interaction Effects in Comparative Bioavailability StudiesHelmut Schütz, Divan A Burger, Erik Cobo, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The AAPS Journal|May 6, 2024
Correction: Group-by-Treatment Interaction Effects in Comparative Bioavailability StudiesHelmut Schütz, Divan A Burger, Erik Cobo, et al.
The AAPS Journal|April 17, 2024
Group-by-Treatment Interaction Effects in Comparative Bioavailability StudiesHelmut Schütz, Divan A Burger, Erik Cobo, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Pageof 2